•
Dec 31, 2019
Solid Biosciences Q4 2019 Earnings Report
Solid Biosciences reported Q4 2019 financial results and provided a business update.
Key Takeaways
Solid Biosciences reported financial results for the fourth quarter and full year ending December 31, 2019. The company is focused on advancing its lead program, SGT-001, a gene therapy candidate for Duchenne muscular dystrophy and is working to address the IGNITE DMD clinical hold.
Biomarker data from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provides further support for continued development
50-70% of the muscle fibers were determined to express SGT-001 microdystrophin in the third patient dosed.
The company announced changes to its organizational structure to create a leaner company focused on advancing SGT-001.
Solid expects that it has sufficient capital to fund its operations into 2021.